Evidence map›Paper›PMID 42450261›Full record

ArticleInternational journal of molecular sciences2026

Structural and Biophysical Analyses of Human MEK2 in Complex with Two Inhibitors Reveal the Determinants of Isoform-Dependent Inhibitor Binding.

Sang Won Cheon, Eunmi Hwang, Gi Baek Lee, Yoonyoung Heo, Hyoun Sook Kim, Byung Woo Han

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sang Won CheonResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0009-0009-6891-6414
Eunmi HwangResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0009-0000-0216-4277
Gi Baek LeeResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Yoonyoung HeoResearch Institute, National Cancer Center, Goyang 10408, Republic of Korea.
Hyoun Sook KimResearch Institute, National Cancer Center, Goyang 10408, Republic of Korea.ORCID 0000-0003-1095-6463
Byung Woo HanResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0000-0001-7571-3791

Funding

Korea Health Industry Development Institute RS-2023-KH141172National Research Foundation of Korea RS-2023-00218543
6 · The paper itself

Abstract

Selective inhibition of MEK isoforms remains a central challenge in MAPK-targeted drug discovery, largely due to the structural similarity between MEK1 and MEK2. While MEK1 has been extensively characterized, the structural basis of MEK2-specific ligand recognition is not fully understood. Here, we present crystal structures of human MEK2 in complex with the noncompetitive inhibitor U0126 and the allosteric inhibitor refametinib at resolutions of 3.15 Å and 3.30 Å, respectively. Despite a conserved kinase fold, MEK2 exhibits isoform-specific features within the N-lobe β-sheet. Additional differences are observed in the relative orientation of the helix C and activation segment, and the helix F-supported regulatory spine. Structural differences are reflected in micromolar binding affinities for U0126 (

Indexed as

ButadienesMAP Kinase Kinase 2NitrilesProtein Kinase InhibitorsBinding SitesCrystallography, X-RayHumansMAP Kinase Kinase 1Models, MolecularProtein BindingProtein ConformationProtein IsoformsButadienesMAP2K2 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2NitrilesProtein IsoformsProtein Kinase InhibitorsU 0126allosteric inhibitorMEK1/2molecular dynamicsnon-competitive inhibitoroligomeric state difference

Identifiers

PMID42450261
PMCPMC13360787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.